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Abstract—Various derivatives of glaziovianin A, an antitumor isoflavone, were synthesized, and the cytotoxicity of each against HeLa 
S3 cells was investigated. Compared to glaziovianin A, the O7-allyl derivative was found to be more cytotoxic against HeLa S3 cells and a 
more potent M-phase inhibitor. ©2000 Elsevier Science Ltd. All rights reserved. 
In 2007, glaziovianin A (1) was isolated from the leaves 
of the Brazilian tree Astelia glazioviana by Yokosuka et 
al. (Fig. 1).1 Glaziovianin A (1) exhibited cytotoxicity 
against HL-60 cells with an IC50 value of 0.29 M. Also, 
glaziovianin A (1) was evaluated against a panel of 39 
human cancer cell lines (termed JFCR39) at the 
Japanese Foundation for Cancer Research. The pattern 
of the differential cytotoxicities of glaziovianin A (1) 
has suggested that the activity of glaziovianin A (1) 
involves the inhibition of tubulin polymerization as a 
mechanism of action.2 Inhibitors of tubulin 
polymerization have become clinically important drugs 
against breast cancer. Because glaziovianin A showed 
antitumor activities in a mouse xenograft model 
(unpublished data), we think that modification of 
glaziovianin A (1) can lead to the discovery of novel 
compounds that possess antitumor activity and that 
inhibit tubulin polymerization. In this paper, we report 
the structure–activity relationship study of glaziovianin 
A (1).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of glaziovianin A (1). 
 
We previously reported the synthesis of glaziovianin A 
(1) by using Suzuki–Miyaura coupling as a key step 
(Scheme 1).3 The method of synthesizing glaziovianin 
A analogues was based on our previous strategy. To 
develop analogues of glaziovianin A (1), its structure 
can be divided into two structural moieties: an A-ring 
and a B-ring (Fig. 2). Therefore, we synthesized 3-
iodochromone derivatives as an A-ring and borone 
compounds as a B-ring. 
 
  
 
Scheme 1. Total synthesis of glaziovianin A (1) by our group. 
 
 
Figure 2. Key structural moieties of glaziovianin A. 
 
First, we tried to modify a methylene acetal part at the 
B-ring of glaziovianin A (Scheme 2). The diol group in 
3,6-dimethoxybenzene-1,2-diol (6) was converted to 
compound 7. The bromination of compound 7 gave a 
monobromo compound, which was converted into 
arylboronate 8.4 2,3,4,5-Tetramethoxyphenylboronic 
acid (10) was prepared by the lithiation of 1,2,3,4-
tetramethoxybenzene (9) followed by treatment with 
trimethyl borate.5 The Suzuki–Miyaura coupling6 of 3-
iodo-6,7-dimethoxy-4H-chromen-4-one (3)3 with boron 
compounds, such as arylboronate 8, 2,3,4,5-
tetramethoxyphenylboronic acid (10), or commercially 
available 3,4-(methylenedioxy)phenylboronic acid (11), 
afforded glaziovianin A analogues 12–14, respectively.   
 
 
Scheme 2. Synthesis of B-ring analogues of glaziovianin A. Reagents and 
conditions: (a) 2-methoxypropene, PPTS, benzene, rt, 72%; (b) NBS, 
DMF, rt, 69%; (c) bis(pinacolato)diboron, PdCl2(dppf), KOAc, DMF, 
150 °C, 28%; (d) n-BuLi, B(OMe)3, THF, rt; (e) 3, PdCl2(dppf), 1 M 
Na2CO3 aq., 1,4-dioxane, rt {64% for 12, 11% for 13 (from 9), 41% for 
14}. 
 
Next, we prepared A-ring analogues. Selective 
protection of the hydroxy group at the C7 position of 
157 afforded compound 16 (Scheme 3). Condensation of 
16 with N,N-dimethylformamide dimethyl acetal gave 
an enamine, which was converted to iodochromone 17.8 
We tried a cross coupling reaction with arylboronate 53 
and iodochromone compounds, such as 17 or 189, to 
provide compounds 19 and 20, respectively. The THP 
group in 19 was removed by using p-TsOH·H2O to give 
a 7-hydroxy derivative (21), which is a suitable 
precursor for the synthesis of glaziovianin derivatives. 
Conversion of the hydroxy group at C7 in 21 into 
various ethers afforded benzyl ether 22, propargyl ether 
23, and allyl ether 24. 
 
  
 
Scheme 3. Synthesis of A-ring analogues of glaziovianin A. Reagents and 
conditions: (a) DHP, PPTS, CH2Cl2, rt, 80%; (b) Me2NCH(OMe)2, 90 °C, 
quant; (c) I2, pyr, CHCl3, rt, 70%; (d) 5, PdCl2(dppf), 1 M Na2CO3 aq., 
1,4-dioxane, rt (66% for 19, 16% for 20); (e) p-TsOH·H2O, MeOH, 
CHCl3, rt, 85%; (f) benzyl bromide, K2CO3, MeCN, rt, 80%; (g) allyl 
bromide, K2CO3, MeCN, rt, 78%; (h) propargyl bromide, K2CO3, MeCN, 
rt, 70%. 
 
Table 1 summarizes the cytotoxicity of glaziovianin A 
(1) and its analogues against HeLa S3 cells.10 
Compound 12, which has an acetonide group instead of 
the methylene acetal group, showed no cytotoxicity 
even at 100M. Also, compound 13, which has four 
methoxy groups at the B-ring, was about 40-fold less 
cytotoxic than glaziovianin A (1). These results 
indicated that steric hindrance of C3’ and C4’ at the B-
ring part was shown to reduce cytotoxicity to a large 
extent. Compound 14, which lacks methoxy groups at 
C2’ and C5’, was less cytotoxic than glaziovianin A (1), 
which indicated that the electron density of the B-ring 
might be essential for cytotoxicity. On the other hand, 
compound 20, which has an extra methoxy group at C5 
of the A-ring, showed no cytotoxicity at 100M. This 
result showed that the steric hindrance and electron 
density of the A-ring reduced cytotoxicity to a large 
extent. While the 7-demethyl derivative 21 exhibited no 
cytotoxicity, compounds 22–24, which each have an 
alkyl group at O7 instead of the methyl group, showed 
cytotoxicity with IC50 values of 0.75, 0.74, and 0.19 M, 
respectively. Furthermore, compound 19, which has a 
THP group at O7, showed no cytotoxicity even at 
100M. These results indicated that the hydrophobicity 
of the O7-alkyl group in glaziovianin derivatives is 
important for cytotoxicity. However, the THP group 
seems to be too large. It is worth noting that allyl ether 
2411 is more active than glaziovianin A (1) itself. 
 
Table 1. Cytotoxicity of glaziovianin A (1) and its analogues against 
HeLa S3 cells. 
 cytotoxicity 
compound IC50 (M) relative value 
glaziovianin A (1) 0.59 1   
12 >100 - 
13 22.0 0.027 
14 56.2 0.010 
19 >100 - 
20 >100 - 
21 >100 - 
22 0.75 0.79 
23 0.74 0.80 
24 0.19 3.1 
 
We previously reported that glaziovianin A (1) inhibited 
the cell cycle progression in the M-phase with abnormal 
spindle structures.1 Therefore, we next investigated the 
effects of the most cytotoxic compound, 24, on both cell 
cycle progression12 and spindle structures13 (Figure 3). 
As with glaziovianin A (1), compound 24 inhibited cell 
cycle progression in M-phase, and 24-treated cells 
showed abnormal spindle structures with unaligned 
chromosomes at the concentration of 1 µM after 18 h 
treatment: these phenotypes were stronger than those of 
1 µM glaziovianin A (1) treatment, suggesting that 
compound 24 is a more potent M-phase inhibitor than 
the original compound glaziovianin A (1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effects of glaziovianin A (1) and compound 24 on cell cycle 
progression and spindle structures in HeLa S3 cells. Effects of 1 and 24 on 
cell cycle progression (A–C) and spindle structures (D–F) in HeLa S3 
cells. HeLa S3 cells were treated with DMSO (A and D), 1 µM of 
glaziovianin A (1) (B and E), or compound 24 (C and F) for 18 h. 
Microtubules (red) and chromosomes (blue) are shown in D–F. 
Microtubules and chromosomes were stained with anti-α-tubulin antibody 
(DM1A, Sigma) and Hoechst 33258, respectively.  
 
In conclusion, we have investigated the structure–
cytotoxicity relationships of glaziovianin A (1). From 
this work, we developed the O7-allyl compound 24 as 
much more cytotoxic than glaziovianin A (1) against 
HeLa S3 cells. Further studies on the synthesis of O7-
  
modified probe molecules of glaziovianin A (1) for 
searching target biomolecules are currently in progress. 
 
Acknowledgments 
 
This work was supported in part by Grants-in-Aid for 
Scientific Research (B), and Scientific Research on 
Priority Area “Creation of Biologically Functional 
Molecules” from the Ministry of Education, Culture, 
Sports, Science and Technology (MEXT), Japan. 
 
References and Notes 
 
1.  Yokosuka, A.; Haraguchi, M.; Usui, T.; Kazami, S.; 
Osada, H.; Yamori, T.; Mimaki, Y. Bioorg. Med. 
Chem. Lett. 2007, 17, 3091. 
2.  Yamori, T.; Matsunaga, A.; Saito, S.; Yamazaki, K.; 
Komi, A.; Ishizu, K.; Mita, I.; Edatsugi, H.; Matsuda, 
Y.;  Takezawa, K.; Nakanishi, O.; Kohno, H.; 
Nakajima, Y.; Komatsu, H.; Andoh, T.; Tsuruo, T. 
Cancer Res. 1999, 59, 4042. 
3.  Hayakawa, I.; Ikedo, A.; Kigoshi, H. Chem. Lett. 
2007, 36, 1382. 
4.  Ishiyama, T.; Murata, M.; Miyaura, N. J. Org. Chem. 
1995, 60, 7508. 
5. Tremblay, S. M.; Sames, D. Org. Lett. 2005, 7, 2417. 
6.  Hoshino, Y.; Miyaura, N.; Suzuki, A. Bull. Chem. 
Soc. Jpn. 1988, 61, 3008. 
7.  Adityachaudhury, N.; Kirtaniya, C. L.; Mukherjee, B. 
Tetrahedron 1971, 27, 2111. 
8.  Gammill, R. B. Synthesis 1979, 901.  
9.  Igarashi, Y.; Kumazawa, H.; Ohshima, T.; Satomi, 
H.; Terabayashi, S.; Takeda, S.; Aburada, M.; 
Miyamoto, K. Chem. Pharm. Bull. 2005, 53, 1088. 
10. Cell survival was determined by a WST-8 assay kit 
(Dojindo Laboratories, Kumamoto, Japan). HeLa S3 
cells (3×103 cells/well) in 96 well plates were 
incubated overnight. Then, cells were treated with 
various concentrations of each compounds. After 48 h 
incubation, 10 µl of WST-8 reagents were added to 
the culture. After 2 h incubation, the absorbance at 
450 nm was measured with iMark microplate reader 
(BioRad Laboratories, Inc). Absorbance correlates 
with the number of living cells. The number of living 
cells (% control) was calculated with the following 
formula: (each absorbance - absorbance of blank 
well)/absorbance of 0 µM well×100. 
11.  Chemical data for compound 24: 1H NMR (400 MHz, 
CDCl3)  7.89 (s, 1H), 7.62 (s, 1H), 6.89 (s, 1H), 6.52 
(s, 1H), 6.11 (ddt, J = 17.6, 10.5, 5.4 Hz, 1H), 6.02 (s, 
2H), 5.48 (ddt, J = 17.6, 1.4, 1.4 Hz, 1H), 5.38 (ddt, J 
= 10.5, 1.4, 1.4 Hz, 1H), 4.72 (dt, J = 5.4, 1.4 Hz, 2H), 
3.98 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H); 13C NMR 
(67.8 MHz, CDCl3)  175.2, 154.4, 153.4, 152.0, 
147.8, 139.0, 138.9, 137.0, 136.6, 135.8, 121.5, 118.0, 
117.7, 116.5, 110.0, 105.2, 101.8, 100.9, 73.3, 62.1, 
57.0, 56.4; IR (CHCl3) 3008, 2938, 1639, 1607, 1503, 
1469, 1430, 1399, 1349, 1298, 1267, 1231, 1195, 
1153, 1099, 1063, 1035, 995, 833, 697 cm— 1; ESIMS 
m/z 435.1057, calcd for C22H20NaO8 [M+Na]+ 
435.1056. 
12.  Flow cytometry was used to analyses the distribution 
of DNA content in the cell populations. The cells 
were fixed with cold (–20 °C) 70% EtOH (v/v) and 
stained with propidium iodide (Sigma). Total 
fluorescence intensities were determined by 
quantitative flow cytometry with CyFlow PA (Partec 
GmbH, Munster, Germany). 
13. Immunofluorescence observation of tubulin was 
performed as described in previous paper.14 The DNA 
and microtubules were photographed with Leica 
AF6000 (Leica Microsystems GmbH, Wetzlar, 
Germany).  
14. Kondoh, M.; Usui, T.; Nishikiori, T.; Mayumi, T.; 
Osada, H. Biochem. J. 1999, 340, 411. 
 
 
 
